Results from CIRSE multicentre registry reinforce safety of St Jude Medical vascular closure device

91

Registry results confirm the excellent sealing performance of Angio-Seal vascular closure devices in interventional radiology procedures.

St Jude Medical commends the efforts of the investigators in the CIRSE Vascular Closure Device Registry, the world’s first multicentre registry aimed at assessing the performance of vascular closure devices in interventional radiology procedures.

With more than 1,100 patients enrolled at 28 centres in 10 European countries, the CIRSE registry validated the routine use of Angio-Seal vascular closure devices in interventional radiology, with successful deployment achieved in approximately 97% of procedures. The registry was conducted under the leadership of principal investigator Jim A Reekers, professor of interventional radiology at the University of Amsterdam, The Netherlands, and confirmed that the use of Angio-Seal vascular closure devices in IR procedures is safe and effective with low incidence of serious complications.

“The CIRSE Vascular Closure Device Registry results provide physicians with an unbiased source of information that verifies the benefits of closure devices in interventional radiology procedures,” Reekers said. “The results offer strong clinical data that demonstrate the use of Angio-Seal vascular closure devices are safe and effective with outstanding deployment success rates.”

The Angio-Seal vascular closure device platform is designed to enable physicians to quickly and effectively seal femoral artery punctures made during minimally invasive catheter-based procedures.

Effectively sealing the puncture helps achieve haemostasis (cessation of bleeding) quickly, enabling the patient to walk and resume activities sooner than with manual compression.

Since its introduction to the market 15 years ago, more than 15 million Angio-Seal vascular closure devices have been utilised around the world. In addition, more than 325 studies have documented the potential benefits of Angio-Seal devices for physicians, patients and hospitals.

“This registry once again confirms the exceptional safety and efficacy profile of Angio-Seal, and adds to previous studies that have indicated increased lab efficiency, reduced procedural cost and improved patient outcomes as a result of the use of this technology,” said Frank Callaghan, president of the St Jude Medical Cardiovascular Division. “St Jude Medical is pleased to see the benefits of our Angio-Seal vascular closure device reinforced by the results from the CIRSE registry, and we anticipate that these results will encourage the use of our Angio-Seal vascular closure device platform in IR procedures.”